The BCG strain pool: Diversity matters

Molecular Therapy

Volumn 24, Issue 2, 2016, Pages 201-203

  Bottai, Daria ^a   Brosch, Roland ^b  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6;

BACTERIAL GENETICS; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BCG VACCINATION; CLINICAL TRIAL (TOPIC); CYTOPLASM; DENDRITIC CELL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; GENETIC VARIABILITY; GENOMICS; GENOTYPE; GLPD2 GENE; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INCIDENCE; MACROPHAGE; MEDICAL RESEARCH; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM BOVIS BCG STRAIN DU2 II; MYCOBACTERIUM BOVIS BCG STRAIN DU2 IV; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; PHENOTYPE; PROMOTER REGION; RECOMBINANT INBRED STRAIN; SEVERE COMBINED IMMUNODEFICIENCY; TUBERCULOSIS; MYCOBACTERIUM BOVIS; DISEASE MODEL; DRUG APPROVAL; EXPERIMENTAL ANIMAL; INFECTION PREVENTION; MOLECULAR THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM;

HUMANS; MYCOBACTERIUM BOVIS;

EID: 84959479605     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.18     Document Type: Note

References (23)

1. Ritz, N, Hanekom, WA, Robins-Browne, R, Britton, WJ and Curtis, N (2008). Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev 32: 821-841.
2. Oettinger, T, Jorgensen, M, Ladefoged, A, Haslov, K and Andersen, P (1999). Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuber Lung Dis 79: 243-250.
3. Zhang, L, Ru, H-w, Chen, F-z, Jin, C-y, Sun, R-f, Fan, X-y, et al. (2016). Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms. Mol Ther 24: 398-405.
4. Whole Mycobacteria Cell Vaccines for Tuberculosis Summary Group (2015). Developing whole mycobacteria cell vaccines for tuberculosis: workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, 9 July 2014. Vaccine 33: 3047-3055.
5. Grode, L, Ganoza, CA, Brohm, C, Weiner, J 3rd, Eisele, B and Kaufmann, SH (2013). Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 31: 1340-1348.
6. Spertini, F, Audran, R, Chakour, R, Karoui, O, Steiner-Monard, V, Thierry, AC, et al. (2015). Safety of human immunisation with a live-Attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med 3: 953-962.
7. Behr, MA, Wilson, MA, Gill, WP, Salamon, H, Schoolnik, GK, Rane, S, et al. (1999). Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284: 1520-1523.
8. Brosch, R, Gordon, SV, Garnier, T, Eiglmeier, K, Frigui, W, Valenti, P, et al. (2007). Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 104: 5596-5601.
9. Abdallah, AM, Hill-Cawthorne, GA, Otto, TD, Coll, F, Guerra-Assunção, JA, Gao, G, et al. (2015). Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations. Sci Rep 5: 15443.
10. Garcia Pelayo, MC, Uplekar S, Keniry, A, Mendoza Lopez, P, Garnier, T, Nunez Garcia, J, et al. (2009). A comprehensive survey of single nucleotide polymorphisms (SNPs) across Mycobacterium bovis strains and M. bovis BCG vaccine strains refines the genealogy and defines a minimal set of SNPs that separate virulent M. bovis strains and M. bovis BCG strains. Infect Immun 77: 2230-2238.
11. Copin, R, Coscolla, M, Efstathiadis, E, Gagneux, S and Ernst, JD (2014). Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG). Vaccine 32: 5998-6004.
12. Lagranderie, MR, Balazuc, AM, Deriaud, E, Leclerc, CD and Gheorghiu, M. (1996). Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun 64: 1-9.
13. Dubos, RJ and Pierce, CH (1956). Differential characteristics in vitro and in vivo of several substrains of BCG. Am Rev Tuberc 74: 655-717.
14. Mahairas, GG, Sabo, PJ, Hickey, MJ, Singh, DC and Stover, CK (1996). Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 178: 1274-1282.
15. Harboe, M, Oettinger, T, Wiker, HG, Rosenkrands, I and Andersen, P (1996). Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun 64: 16-22.
16. Majlessi, L, Prados-Rosales, R, Casadevall, A and Brosch, R (2015). Release of mycobacterial antigens. Immunol Rev 264: 25-45.
17. Pym, AS, Brodin, P, Majlessi, L, Brosch, R, Demangel, C, Williams, A, et al. (2003). Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 9: 533-539.
18. Bottai, D, Frigui, W, Clark, S, Rayner, E, Zelmer, A, Andreu, N, et al. (2015). Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. Vaccine 33: 2710-2718.
19. Etna, MP, Giacomini, E, Pardini, M, Severa, M, Bottai, D, Cruciani, M, et al. (2015). Impact of Mycobacterium tuberculosis RD1-locus on human primary dendritic cell immune functions. Sci Rep. 5: 17078.
20. Majlessi, L and Brosch, R. Mycobacterium tuberculosis meets the cytosol: the role of cGAS in anti-mycobacterial immunity. Cell Host Microbe 17: 733-735.
21. Simeone, R, Sayes, F, Song, O, Gröschel, MI, Brodin, P, Brosch, R, et al. (2015). Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo. PLoS Pathog 11: e1004650.
22. Chen, JM, Islam, ST, Ren, H and Liu, J (2007). Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety. Vaccine 25: 8114-8122.
23. Gonzalo-Asensio, J, Malaga, W, Pawlik, A, Astarie-Dequeker, C, Passemar, C, Moreau, F, et al. (2014). Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator. Proc Natl Acad Sci USA 111: 11491-11496.